Powered by Oncomine™ from Thermo Fisher Scientific
Next-Gen Sequencing Lung Panel Based on Technologies of Biocept and Thermo Fisher Scientific
Combining Biocept’s Liquid Biopsy biomarker testing expertise with Oncomine™ from Thermo Fisher Scientific’s next-generation sequencing and decision support resources.
- Exclusive, targeted and actionable; approximately 70% of biomarkers investigated are based on NCCN Guidelines and/or FDA approved therapies
- Cost effective NGS-based solution
- Turn-around-time (7-10 days upon receipt of specimen in most cases)
- Specimen requirements: 8 mLs of peripheral blood in CEE-SURE™ or EDTA Tube
- Sensitivity: 96-99% (MAF ≥0.1%)
- Raw data file available for further research
Current Gene List
All genes in blue font are referenced in NCCN Guidelines and/or are associated with FDA-approved therapy.